...
首页> 外文期刊>Cukurova Medical Journal >Evaluation of Oral Prostaglandin E1 in Management of Ductus Dependent Congenital Heart Disease
【24h】

Evaluation of Oral Prostaglandin E1 in Management of Ductus Dependent Congenital Heart Disease

机译:口服前列腺素E1治疗导管依赖型先天性心脏病的评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Intravenous prostaglandin E1 (PGE1) infusion is a treatment which has been proven to be effective in ductus dependent congenital heart disease. However, PGE1 is very expensive, needed continuous infusion and its supply is difficult by every center. When its long term use is necessary, these problems become more important. The aim of this study was to show whether oral PGE1could keep the ductus open or not till the supply of intravenous PGE1. Method: Ten patients, who were admitted to newborn intensive care unit with the diagnosis of ductus dependent congenital heart disease and received oral PGE1 till the supply of intravenous PGE1, were evaluated. The PO2 with the arterial blood gas analysis and SO2 levels with pulse oxymeter at skin were recorded before and after the administration of oral and intravenous PGE1. Results: The mean oral PGE1 initiation age was 5.5 hours (0.5-25), and mean administration period was 28 hours (18-46). It was observed that the PO2 and SO2 levels of patients measured 2 hours after the initiation of oral PGE1 were significantly increased compared to the levels before initiation of PGE1. The improvement in PO2 and SO2 levels continued till the initiation of intravenous PGE1. It was also observed that the PO2 and SO2 levels of patients measured 2 hours after the initiation of intravenous PGE1 were slightly increased compared to levels before initiation of intravenous PGE1. Conclusion: Although intravenous PGE1 is more effective than oral PGE1 in short term usage, oral PGE1 is also sufficiently effective in keeping the dustus open. For this reason until the intravenous PGE1 is supplied oral PGE1 may be used as an alternative treatment choice. We think that in long term use oral PGE1, which is cheaper and easy to use, could be used instead of intravenous PGE1 without need of admission to hospital and opening intravenous line. However for this further studies are needed to confirm this assumption.
机译:目的:静脉注射前列腺素E1(PGE1)是一种已被证明可有效治疗导管依赖型先天性心脏病的治疗方法。但是,PGE1非常昂贵,需要连续输注,并且每个中心都难以供应。当需要长期使用时,这些问题变得更加重要。这项研究的目的是显示口服PGE1在静脉内提供PGE1之前是否可以保持导管开放。方法:对十例患者进行了评估,这些患者被诊断为患有导管依赖型先天性心脏病的新生儿重症监护病房,并在口服PGE1之前接受口服PGE1。在口服和静脉注射PGE1之前和之后,记录具有动脉血气分析的PO2和通过脉搏血氧仪测得的SO2水平。结果:口服PGE1的平均起始年龄为5.5小时(0.5-25),平均给药时间为28小时(18-46)。观察到,与口服PGE1之前相比,口服PGE1服用2小时后测量的患者的PO2和SO2水平显着增加。 PO2和SO2水平的改善一直持续到开始静脉注射PGE1为止。还观察到,与开始静脉注射PGE1之前相比,开始静脉注射PGE1 2小时后测量的患者的PO2和SO2水平略有增加。结论:尽管短期使用静脉内PGE1比口服PGE1更有效,但口服PGE1在保持灰尘开放方面也足够有效。因此,在提供静脉注射PGE1之前,口服PGE1可用作替代治疗选择。我们认为,长期使用便宜且易于使用的口服PGE1可以代替静脉注射PGE1,而无需住院和开放静脉管线。但是,为此需要进一步的研究以确认这一假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号